Classification of lower- and higher-risk MDS patients.
| Lower-risk MDS Survival of 3–10 years Low rate of AML transformation . | Higher-risk MDS Survival <1.5 years High rate of AML transformation . |
|---|---|
| MDS indicates myelodysplastic syndromes; AML, acute myeloid leukemia; RA, refractory anemia; RARS, RA with ring sideroblasts; RCUD, refractory cytopenia with unlineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; MDS-U, MDS unclassifiable; IPSS, International Prognostic Scoring System; RAEB, RA with excess blasts | |
| RA, RARS | RAEB (−1, −2) |
| RCUD, RCMD | IPSS Int-2, High (Score ≥ 1.5) |
| MDS-U, MDS del(5q) | |
| IPSS Low, Int-1 (Score 0–1.0) | |
| Lower-risk MDS Survival of 3–10 years Low rate of AML transformation . | Higher-risk MDS Survival <1.5 years High rate of AML transformation . |
|---|---|
| MDS indicates myelodysplastic syndromes; AML, acute myeloid leukemia; RA, refractory anemia; RARS, RA with ring sideroblasts; RCUD, refractory cytopenia with unlineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; MDS-U, MDS unclassifiable; IPSS, International Prognostic Scoring System; RAEB, RA with excess blasts | |
| RA, RARS | RAEB (−1, −2) |
| RCUD, RCMD | IPSS Int-2, High (Score ≥ 1.5) |
| MDS-U, MDS del(5q) | |
| IPSS Low, Int-1 (Score 0–1.0) | |